Belpointe Asset Management LLC purchased a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) during the third quarter, Holdings Channel reports. The fund purchased 6,993 shares of the exchange traded fund’s stock, valued at approximately $701,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Capital A Wealth Management LLC bought a new stake in shares of SPDR S&P Biotech ETF in the second quarter valued at $26,000. DHJJ Financial Advisors Ltd. bought a new stake in shares of SPDR S&P Biotech ETF in the second quarter valued at approximately $25,000. Davis Capital Management bought a new stake in shares of SPDR S&P Biotech ETF in the third quarter valued at approximately $35,000. Twin Peaks Wealth Advisors LLC bought a new position in SPDR S&P Biotech ETF in the 2nd quarter worth approximately $32,000. Finally, Johnson Financial Group Inc. purchased a new position in SPDR S&P Biotech ETF in the 2nd quarter valued at approximately $31,000.
SPDR S&P Biotech ETF Price Performance
NYSEARCA:XBI opened at $124.75 on Friday. SPDR S&P Biotech ETF has a 1 year low of $66.66 and a 1 year high of $132.09. The stock’s fifty day moving average price is $123.78 and its two-hundred day moving average price is $107.11. The company has a market cap of $8.45 billion, a P/E ratio of 11.47 and a beta of 0.93.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
- The Crash Has Already Started (Most Just Don’t See It Yet)
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
